


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華控康泰集團有限公司

Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

FURTHER DELAY IN DESPATCH OF CIRCULAR IN RELATION TO A MAJOR TRANSACTION

Reference is made to (i) the announcement of Kontafarma China Holdings Limited (the “**Company**”) dated 27 July 2026 in relation to renewal of lease for an existing fitness and yoga centre (the “**Announcement**”); and (ii) the announcement of the Company dated 17 August 2026 in relation to the delay in despatch of the Circular (the “**Delay Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement and the Delay Announcement.

As disclosed in the Delay Announcement, the Circular containing, among other things, (i) information on the New Lease; and (ii) other information required under the Listing Rules, was expected to be despatched to the Shareholders on or before 4 September 2026.

As additional time is required for the Company to finalise the information set out in the Circular, the Company is applying to the Stock Exchange for a second waiver from strict compliance with the requirements of Rule 14.41(a) of the Listing Rules (the “**Second Waiver**”). Subject to the Stock Exchange granting the Second Waiver to the Company, the Company expects that the despatch date of the Circular will be postponed to a date on or before 24 September 2026.

By order of the Board of
Kontafarma China Holdings Limited
Wang Limin
Chairman

Hong Kong, 4 September 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Limin (Chairman), Mr. Li Qingshan (President), Mr. Ge Shouwen (Vice President), and Ms. Guo Zixiu (Financial Controller); and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.